Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.50 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.50 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.50 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.44 |
| ▸ | IGF1R | P08069 | 9/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402326 | 0.91 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL8404282 | 0.91 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL10242666 | 0.89 | TNK2 (0.53) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL8402258 | 0.89 | PIK3CA (0.46) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL8404219 | 0.85 | PIK3CA (0.51) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL8401090 | 0.81 | TNK2 (0.53) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL13629425 | 0.80 | TNK2 (0.47) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL8402287 | 0.80 | TNK2 (0.47) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL13629022 | 0.80 | PIK3CA (0.49) | PIK3CAPIK3CBMTORPIK3CGPRKDC | |
| SCHEMBL12648246 | 0.80 | TNK2 (0.49) | PIK3CAPIK3CBMTORPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | PIK3CA 25/4885PIK3CB 92/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.